Nutrien Valuation

Is N7T undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of N7T when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: N7T (€44.24) is trading below our estimate of fair value (€61.23)

Significantly Below Fair Value: N7T is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for N7T?

Key metric: As N7T is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for N7T. This is calculated by dividing N7T's market cap by their current earnings.
What is N7T's PE Ratio?
PE Ratio31.1x
EarningsUS$733.00m
Market CapUS$22.79b

Price to Earnings Ratio vs Peers

How does N7T's PE Ratio compare to its peers?

The above table shows the PE ratio for N7T vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average56.8x
SDF K+S
78.5x61.1%€2.0b
BAS BASF
76.2x34.2%€37.9b
SY1 Symrise
37.2x13.3%€14.6b
EVK Evonik Industries
35.3x33.1%€8.1b
N7T Nutrien
31.1x34.8%€31.9b

Price-To-Earnings vs Peers: N7T is good value based on its Price-To-Earnings Ratio (31.1x) compared to the peer average (56.8x).


Price to Earnings Ratio vs Industry

How does N7T's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
N7T 31.1xIndustry Avg. 16.8xNo. of Companies12PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: N7T is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the European Chemicals industry average (17.3x).


Price to Earnings Ratio vs Fair Ratio

What is N7T's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

N7T PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.1x
Fair PE Ratio28.9x

Price-To-Earnings vs Fair Ratio: N7T is expensive based on its Price-To-Earnings Ratio (31.1x) compared to the estimated Fair Price-To-Earnings Ratio (28.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst N7T forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€44.24
€51.96
+17.4%
18.8%€66.20€35.40n/a7
Nov ’25€44.16
€51.60
+16.8%
19.4%€64.81€34.42n/a7
Oct ’25€43.40
€48.53
+11.8%
19.3%€62.55€33.22n/a7
Sep ’25€43.55
€52.34
+20.2%
17.3%€63.42€39.01n/a7
Aug ’25€46.00
€57.44
+24.9%
16.5%€67.69€41.70n/a7
Jul ’25€47.34
€59.98
+26.7%
12.5%€70.44€46.39n/a7
Jun ’25€53.24
€59.10
+11.0%
12.5%€69.28€45.74n/a7
May ’25€50.24
€58.35
+16.2%
15.5%€70.15€45.99n/a8
Apr ’25€49.30
€57.23
+16.1%
15.2%€69.87€44.62n/a8
Mar ’25€48.20
€58.89
+22.2%
15.2%€72.61€45.20n/a8
Feb ’25€47.15
€62.05
+31.6%
9.9%€72.64€53.35n/a8
Jan ’25€50.90
€62.83
+23.4%
12.6%€80.49€52.88n/a8
Dec ’24€49.10
€62.73
+27.8%
12.8%€80.44€52.31n/a8
Nov ’24€50.70
€65.38
+28.9%
12.6%€83.15€55.15€44.168
Oct ’24€59.80
€64.39
+7.7%
11.4%€80.50€54.91€43.408
Sep ’24€58.30
€64.39
+10.5%
11.4%€80.50€54.91€43.558
Aug ’24€61.40
€64.75
+5.5%
12.8%€82.86€56.08€46.007
Jul ’24€54.40
€70.05
+28.8%
16.0%€92.50€57.51€47.346
Jun ’24€49.25
€72.19
+46.6%
14.3%€93.81€64.78€53.246
May ’24€62.40
€82.17
+31.7%
10.0%€97.38€72.52€50.246
Apr ’24€66.96
€84.70
+26.5%
13.9%€108.40€72.95€49.306
Mar ’24€73.29
€87.60
+19.5%
13.8%€112.07€75.42€48.206
Feb ’24€75.41
€88.46
+17.3%
13.8%€110.07€74.80€47.156
Jan ’24€68.35
€95.04
+39.1%
15.6%€124.19€78.12€50.906
Dec ’23€75.89
€95.04
+25.2%
15.6%€124.19€78.12€49.106
Nov ’23€85.06
€110.24
+29.6%
16.6%€139.96€86.06€50.706

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies